ProMIS Neurosciences, Inc.
PMNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 21, 2026 | Roth Capital | $29.00(+91%) | $15.15 | TheFly | |
| Jul 28, 2026 | Chardan Capital | Keay Nakae | $33.00(+105%) | $16.07 | TheFly |
| Jul 27, 2026 | Chardan Capital | Keay Nakae | $20.00(+64%) | $12.20 | TheFly |
| Jul 7, 2026 | Roth Capital | $19.00(+40%) | $13.55 | TheFly | |
| Dec 1, 2025 | H.C. Wainwright | $18.00(+149%) | $7.21 | TheFly | |
| Jul 14, 2025 | H.C. Wainwright | Raghuram Selvaraju | $4.00(-87%) | $30.00 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Roth Capital | maintain | Buy | Nov 2, 2026 |
| Guggenheim | maintain | Buy | Aug 14, 2026 |
| Guggenheim | maintain | Buy | Jul 29, 2026 |
| Chardan Capital | maintain | Buy | Jul 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 24, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 8, 2026 |
| Guggenheim | maintain | Buy | Feb 6, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 21, 2025 |
| Guggenheim | maintain | Buy | Nov 18, 2025 |
| Guggenheim | maintain | Buy | Apr 1, 2025 |
| Guggenheim | maintain | Buy | Feb 26, 2025 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-1.26| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-1.28 | $-1.38 | — | — |
| May 11, 2026 | $-1.26 | $-1.06 | — | — |
| Mar 30, 2026 | $-4.11 | $-4.22 | — | — |
| Nov 12, 2025 | $-6.00 | $-3.75 | — | — |
| Aug 13, 2025 | $-7.25 | $-5.50 | — | — |
| May 12, 2025 | $-5.25 | $-3.00 | — | — |
| Mar 31, 2025 | $-0.50 | $-3.50 | — | — |
| Nov 14, 2024 | $0.42 | $-0.07 | — | — |
News
CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming November 2026 conferences. Presentations and fireside chats will be delivered by Neil Warma, President and Chief Executive Officer. Members of the Company's leadership team will be available for one-on-o…
Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.
Cambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the third quarter ended September 30, 2026, and provide corporate updates on November 12, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m.
The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 293% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Former senior Biogen and Roche executive brings deep experience across Alzheimer's clinical development, launch readiness, commercialization and global medical strategy
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.
Promis Neurosciences NASDAQ: PMN reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early Alzheimer's disease.
Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended June 30, 2026, and provided a corporate update.